| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 104.81 | 1-year : | 113.29 |
| Resists | First : | 89.73 | Second : | 97 |
| Pivot price | 83.91  |
|||
| Supports | First : | 77.98 | Second : | 64.88 |
| MAs | MA(5) : | 82.62  |
MA(20) : | 86.03 |
| MA(100) : | 85.72 |
MA(250) : | 71.26 |
|
| MACD | MACD : | -2.5 |
Signal : | -2.6 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 27.2 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 99.5 | Low : | 52.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANIP ] has closed below upper band by 43.3%. Bollinger Bands are 14.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 85.21 - 85.51 | 85.51 - 85.78 |
| Low: | 82.46 - 82.85 | 82.85 - 83.2 |
| Close: | 83.75 - 84.29 | 84.29 - 84.78 |
Fri, 28 Nov 2025
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? - Yahoo Finance
Fri, 28 Nov 2025
First Week of July 2026 Options Trading For ANI Pharmaceuticals (ANIP) - Nasdaq
Fri, 28 Nov 2025
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 26 Nov 2025
Price-Driven Insight from (ANIP) for Rule-Based Strategy - news.stocktradersdaily.com
Tue, 25 Nov 2025
ANI Pharmaceuticals (ANIP): Assessing Valuation After Rare Disease Revenue Surges on Cortrophin Gel Demand - Sahm
Mon, 24 Nov 2025
What ANI Pharmaceuticals (ANIP)'s Rare Disease Revenue Surge Means for Shareholders - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 97.3 (%) |
| Shares Short | 2,500 (K) |
| Shares Short P.Month | 2,330 (K) |
| EPS | 1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.19 |
| Profit Margin | 4.9 % |
| Operating Margin | 10.1 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 53.5 % |
| Gross Profit (p.s.) | 22.36 |
| Sales Per Share | 36.81 |
| EBITDA (p.s.) | 6.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 171 (M) |
| Levered Free Cash Flow | 118 (M) |
| PE Ratio | 53.03 |
| PEG Ratio | 0 |
| Price to Book value | 3.5 |
| Price to Sales | 2.3 |
| Price to Cash Flow | 11.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|